Enhancing domestic laboratory biosafety for Ebola and other highly infectious diseases by Merlin, Toby L. et al.
Enhancing Domestic Laboratory
Biosafety for Ebola and Other 
Highly Infectious Diseases
Toby Merlin, MD
Director, Division of Preparedness and Emerging Infections
Clinical Laboratory Improvement Advisory Committee Meeting
April 14, 2016
National Center for Emerging and Zoonotic Infectious Diseases
Division of Preparedness and Emerging Infections
OUTLINE
 Background information
 Summary of accomplishments & challenges
 Next steps
BACKGROUND INFORMATION
Identified Gaps in Laboratory Safety 
During 2014 US Ebola Event
 Clinical laboratories’ ability to ship specimens for Ebola 
testing was not uniform
 Some laboratories declined requests to test specimens for 
malaria or other more likely diagnoses from persons under 
investigation (PUI) for Ebola
 Instrument decontamination procedures were not 
available
 Inconsistent laboratory response due to:
 The lack of guidance for handling and testing of PUI specimens
 Gaps in laboratory biosafety programs
CDC’s Epidemiology  and Laboratory 
Capacity (ELC) Program to
Enhance Laboratory Biosafety
 $110 million Cooperative Agreement with categorical and 
flexible components
 For public health departments in 50 states, 6 locals, & 8 
territories/affiliates.
 Strengthens the following areas:
 identify and monitor occurrence of known infectious 
diseases,
 detect new emerging infectious disease threats,
 identify and respond to disease outbreaks, and
 develop and evaluate public health interventions. 
ELC Supplemental Awards 
 March 30, 2015 - Funds awarded to 62 grantees -
3 years, $21 million
 Strategy 1: Enhance public health laboratory (PHL) 
biosafety capacity
 Hire or designate a PHL biosafety official (BSO), 
 Update biosafety guidelines
 Conduct risk assessments (RA) and implement risk mitigation 
strategies
 Develop and provide training and tools
 Strategy 2: Improve laboratory coordination and 
outreach
 Work with clinical laboratory (CL) partners to facilitate their risk 
assessments and development/implementation of measures to 
address gaps and mitigate risks 
Role of Association of Public 
Health Laboratories (APHL)
Awarded a 3-year supplement ($2.2 million) to: 
 Serve as subject matter expert for ELC biosafety grantees
 Develop and deliver tools, materials, guidance
 Ensure access to targeted educational and training 
opportunities
 Coordinate national efforts to improve PHL biosafety 
capacity
 Conduct outreach with and engage CL partners





Activities Focused on 
Public Health Laboratories
 97% (60/62) of grantees have hired or designated a BSO 
 As of Oct 2015, performance measurement reports from 
grantees indicated that approximately:
 90% (53/57) had conducted RA for EVD
 82% (50/61) had certified personnel to pack and ship Category A 
specimens 
 71% (40/56) had personnel with demonstrated competency to work 
in a BSL-3 laboratory
 55% (34/61) had policies and/or procedures for conducting RAs
Progress Report:
Activities Focused on 
Clinical Laboratories
 ELC grantees provided performance measurement data for 
CLs in their jurisdictions in May & Oct 2015
 Measures addressed CL capacity for packing & shipping 
specimens to their PHL for Ebola testing and risk 
assessment capabilities
 Most grantees will address CL activities in Years 2 and 3
 A few have started working with CL partners by convening 
meetings, conducting site visits and providing training and 
tools
Performance Measurement Results 
for Clinical Laboratories
As of Oct 2015 –
 33% of the grantees (19/57) reported that 80% of CLs in 
their jurisdiction had at least two staff members certified in 
packaging & shipping 
 8% (5/59) reported 80% of CLs in their jurisdiction had 
completed at least one RA 
 10% (6/60) reported 70% of CLs had a policy and/or 
procedure for performing RA
Summary: Laboratory Performance 
Measures
Public Health Laboratories:
 PHLs are on track to meet targets
 Focus area for improvement = risk assessment process and 
documentation
Clinical Laboratories
 Staffing for packaging and shipping is improving
 Outreach is needed for performing RAs 
APHL Accomplishments
 Hired biosafety subject matter experts
 Convened a Biosafety and Biosecurity Committee (BBC) 
with PHL and CL representatives
 Developed and distributed competency-based BSO job 
description
 Developed and distributed templates to PHLs for Ebola and 
Zika Virus risk assessment and mitigation
 Conducted a needs assessment survey of ELC grantees
 Offered webinars to ELC grantees on 1) basics of biosafety 
& biosecurity, 2) PHL biosafety competencies, and 3) PHL 
outreach to CLs 
Challenges
 The pool of individuals with laboratory biosafety knowledge 
and experience is insufficient to meet the need, resulting in
 Delays in hiring BSOs
 The need for training to bring everyone to a basic level
 Biosafety risk management appears to be a relatively new 
concept in CLs that will require extensive outreach efforts 
to address




 Year 2 continuation guidance published March 14, 2016, 
applications due May 17, 2016
 Additional Ebola funds are available for which ELC grantees 
can apply (e.g. to supplement BSO training)
 ELC grantees will work to enhance outreach to their CL 
partners
 Performance measurement data will be collected in April-
May for the period Oct 1, 2015 to Mar 31, 2016
APHL
 Results from the needs assessment survey will be used to 
target certain activities
 A Biosafety & Biosecurity Partners Forum will be convened 
in 2016 to facilitate information exchange among federal, 
state, clinical laboratory organizations and other 
stakeholders
 Guidance and tools for risk assessments will be developed 
& distributed 
 Checklists to assist with CL outreach are under 
development by the BBC
 Webinars and other training will be provided to the BSOs
 Regional workshops for BSOs will be convened in 2016
Questions?
